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The aim of this study is to analyze MMP-2 and sTNF-R1 variability, potent predictors of cardiovascular events, in stable
hypertensive patients during a 12-month followup. 234 asymptomatic patients (age 60 ± 13, 136 male) out of 252 patients
with essential hypertension were followed up. MMP-2 and sTNF-R1 were measured at baseline and after 12 months (stage I).
To compare MMP-2 and sTNF-R1 levels over time interval, we used the statistical method of Bland-Altman. MMP-2 and sTNF-R1
reproducibility was good in our patients for the two intervals with a coeﬃcient of reproducibility of 8.2% and 11.3%, respectively.
The percentages of patients within 1.96 × standard deviation of the mean were 93.6% and 92.7%. An elevated coeﬃcient of
correlation was obtained for MMP-2, basal versus stage I (r = 0.55, P < 0.0001) and for sTNF-R1 (r = 0.75, P < 0.0001).
There is good stability in MMP-2 and sTNF-R1 levels in a followup study of patients with stable hypertension. As a consequence,
assessment of its concentrations may be a useful tool for monitoring the follow-up of these patients. Measured variations in MMP-
2 and sTNF-R1 levels, exceeding 8.2% and 11.3%, respectively, may indicate an increase in cardiovascular risk, thus, could be used
to optimizing treatment than blood pressure control alone.
1. Background
Sustained hypertension (HT) may cause left ventricular
hypertrophy (LVH), alterations in cardiac function, and
heart failure (HF) [1]. Cardiomyocyte apoptosis has been
shown to contribute to myocardial remodeling in response
to pressure overload in HT [2, 3].
The soluble tumor necrosis factor receptor 1 (sTNF-R1)
represent the classical death signal of the apoptotic process
[4, 5]. Overexpression of myocardial TNF-α is observed
in patients with pressure overload states and cardiac dila-
tion. Evidence supports that circulating sTNF-R1 levels
are increased in patients with HF [6–8], being a powerful
predictor of mortality in HF [9]. In addition, this receptor is
associated with inflammatory disease in HT, it has published
that plasma sTNF-R1 was an independent predictor of left
ventricular mass index and hypertrophy [10].
Changes in the composition of the extracellular matrix
(ECM) are known to occur in HT [11, 12], and these may
lead to cardiac fibrosis and diastolic dysfunction contributing
to the progression of HF and to sudden death [13, 14].
The variations in metalloproteinases (MMPs) expression are
important processes of ventricular remodeling in the patho-
physiology of HT [15] and may contribute to HF and other
cardiac complications in patients with hypertensive heart
disease [12, 16]. The serum levels of matrix MMPs increase
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during chronic HF and metalloproteinase-2 (MMP-2) is
related to diastolic dysfunction [17, 18] and to a poor
prognosis, being predictor of mortality [19–21].
In a recent study, our group has found a good stability
of amino-terminal propeptide of B type natriuretic peptide
(NT-proBNP) levels [22], a powerful predictor of mortality
in hypertensive patients without HF [23]. Furthermore, we
have shown a significant relationship between this natriuretic
peptide and inflammatory status, especially with sTNF-R1
[22]. The knowledge of variations in MMP-2 and sTNF-
R1 levels is crucial when using these molecules as a tool
to monitor the evolution of inflammation activation and
collagen remodeling in hypertensive patients. However, there
are no studies addressing its variability and stability, and
there are no data on the changes in serumMMP-2 and sTNF-
R1 levels over time in asymptomatic stable patients with
essential HT. This would allow us to know the usefulness of
these molecules in the clinical arena.
We hypothesized that inflammatory and fibrosis markers
levels may change over time even in patients with clinically
stable HT. Therefore, the aims of the present study were to
analyze MMP-2 and sTNF-R1 variability during a 12-month
followup, in a cohort of stable hypertensive patients.
2. Methods
2.1. Patients. The study was on 252 Caucasian asymptomatic
consecutive out-patients withmild hypertension (mean (SD)
age 60 (13) years, 136 male), from 11 participating hospitals.
All patients underwent a routine physical examination,
electrocardiogram, echo-Doppler study, and laboratory anal-
yses. Physicians using a standardized protocol measured
systolic and diastolic blood pressure in the left arm of
seated subjects between 08:00 and 11:00 AM, following the
recommendations of The American Heart Association[24].
Of the 252 subjects, 234 asymptomatic (they did not refer any
symptoms of cardiovascular origin, specifically symptoms of
HF) and stable patients (without cardiovascular events [25])
were included in the study (136 with LVH and 98 without
LVH, age 60 ± 13 years, 136 male). Eighteen (7%) were
excluded during the followup (8 refused to continue, 9 could
not be located, and 1 patient had stroke).
Patients analyzed in this study met these inclusion
criteria: a previous diagnosis of hypertension, as defined
by the “seventh report of the joint national committee on
prevention, detection, evaluation, and treatment of high
blood pressure” [24]. Furthermore, exclusion criteria were
secondary HT, left ventricular ejection fraction <50, ischemic
(medical history, echo-Doppler, troponin T assay) or dilated
cardiomyopathy, atrial fibrillation, more than mild valvular
disease, acute and chronic liver or renal diseases, immuno-
logical diseases, HIV, alcoholism and drug addiction, and any
other life-threatening disease.
All patients were on stable medical therapy for at
least 2 months before study enrollment with angiotensin
II receptor antagonist 50%, diuretics 45%, angiotensin-
converting enzyme inhibitors 32%, β-blockers 21%, statins
26%, and calcium-channel blockers 19%. There were not
statistically significant changes in the diﬀerent drugs admin-
istered during followup. None of the 234 patients finally
studied presented cardiovascular events (defined as stroke,
myocardial infarction, or cardiovascular death) [25]. Body
mass index was calculated as the weight in kilograms divided
by height in meters squared, and obesity was defined as
body mass index >30 kg/m2. Glomerular filtration rate was
calculated using the modified diet in renal disease equation
[26]. All patients were followed up until the end of the
study at month 12, with a two-stage sample collection: basal
and 12 months (stage I). All explorations were conducted at
each stage. The procedure was approved by the appropriate
institutional review boards or ethics review committees of
each study center, and the study was conducted in accordance
with the guidelines of good clinical practice and with ethical
standards for human experimentation established by the
Declaration of Helsinki. Every patient signed a written
informed consent for their inclusion in the study.
2.2. Laboratory Determinations. Venous blood was taken by
venipuncture into pyrogen-free vacuum tubes containing
EDTA, and serum was obtained by gel clotter tubes, from
subjects in sitting position between 8:00 and 11:00 AM.
Samples were centrifuged immediately, frozen at−80◦C, and
only thawed once. Plasma concentrations of MMP-2 and
sTNF-R1 were determined at central laboratory by specific
commercial sandwich enzyme-linked immunosorbent assay
(Hbt human sTNF-R1 ELISA test kit, Hycult Biotechnology,
Germany; MMP-2 Human ELISA Kit, Camarillo, CA, USA).
The MMP-2 and sTNF-R1 tests have limits of detection of
0.1 ng/mL and 25 pg/mL, respectively. Our intra-assay and
interassay coeﬃcients of variation were 5.9 and 6.2% for
MMP-2, and 26.5 and 9.1% for sTNF-R1.
2.3. Echo-Doppler Study. The examinations were performed
using standard systems equipped with 2.5–4MHz transduc-
ers. The echocardiographic examinations were performed
using the standard apical and parasternal long axis views
were obtained in all echocardiographic studies and analyzed
by a computerized system (Eco-Dat; Software Medicina
S.A., Madrid, Spain). M-Mode and two-dimensional images,
Doppler spectrum and color Doppler were measured and
averaged for each Doppler variable. For each patient, four
consecutive beats were measured and averaged for each
Doppler variable.
Left ventricular ejection fraction (LVEF) was calculated
with the area-length method [27]. The E/A ratio was also
calculated. Left ventricular mass (LVM) was measured fol-
lowing the Devereux method [28] and indexed for height2.7
due to the high prevalence of obese and overweight patients,
defining LVH as LVM index >46.7 g/m2.7 in women and
>49.2 g/m2.7 in men [29].
2.4. Statistical Analysis. Continuous variables are presented
as mean ± SD and categorical variables as a number
of patients or percentage. Results for each variable were
tested for normality using the Kolmogorov Smirnov method.
MMP-2 and sTNF-R1 concentrations exhibit a nonnormal
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distribution andwere presented as themedian and interquar-
tile range and log transformed (and proved to be normal-
ized) before parametric correlation analysis by Pearson’s
coeﬃcient. Temporal changes in molecule levels and clinical
characteristics were analyzed using the paired student’s t-test
and categorical variable changes were compared using the
McNemar test.
To compare MMP-2 and sTNF-R1 levels over time
interval (stage I-basal stage), we used the statistical method
of Bland-Altman [30, 31]. In this graphical method the
percentage of change in the averages ((molecule stage I-
molecule basal)/(average stage I + basal stage)) is plotted
against the average of the total molecule measurement.
This expression is useful to normalize and compare the
data without taking into account the magnitude of the
molecule measurement. Based on this approach, the limits
of agreement were determined by the mean diﬀerence plus
or minus the coeﬃcient of reproducibility (CR), where CR
was calculated as 1.96 × SD of the percentage of changes. In
this case, a high CR indicates poor reproducibility.
Furthermore, a multivariate linear regression analysis
was performed using log transformed MMP-2 and sTNF-R1
as dependent variables and included gender, blood pressure,
body mass index, LVMI and known HT duration, and
treatment as independent variables. The discrimination of
the best model was based on the principle of least mean
square and higher R-square.
A P value <0.05 was considered significant for all
measures. All statistical analyses were performed using the
SPSS 11.5 statistical software package (SPSS Inc, Chicago,
IL).
3. Results
The baseline characteristics of the 234 hypertensive patients
included in the study in the two stages are shown in Table 1.
Significant diﬀerences in blood pressure and total cholesterol
levels were observed with respect to the basal stage. Body
mass index, heart rate, biochemical values, left ventricular
mass index and diastolic function variables did not show
any statistical change. There were no statistically significant
changes between the diﬀerent drugs administered during the
follow-up. The values for MMP-2 were basal stage, 107 (96–
122) ng/mL, and stage I, 112 (94–129) ng/mL, P < 0.05, and
for sTNF-R1 basal stage, 385 (290–541) pg/mL, stage I, 394
(289–576) pg/mL, with no significant diﬀerences.
We obtained good reproducibility for MMP-2 and sTNF-
R1 measurements for the whole study comparing stage
I-basal stage. Figure 1 shows the Bland-Altman plots for
changes in MMP-2 and sTNF-R1 serum levels in patients
with asymptomatic HT, over the interval studied. The
percentages of patients within 1.96 SD of the mean were
93.6% and 92.7%, respectively. Furthermore, the values of
the mean ± SD percentage change and CR for MMP-2
were 0.6 ± 4.2 with a CR of 8.2% and for sTNF-R1 were
0.5± 5.8 with a CR of 11.3%. In addition, when we analyzed
the correlation between the two molecules in stage I versus
basal stage (Figure 2), we found a significant coeﬃcient of
Table 1: Clinical characteristics of patients with essential hyperten-
sion over the entire study (n = 234): basal, stage I = at 12 months.
Basal (n = 234) Stage I (n = 234)
Age (years) 60 ± 13 61 ± 13
Gender (% male) 54 54
BMI (kg/m2) 30 ± 4 30 ± 4
SBP (mmHg) 149 ± 20 142 ± 11b
DBP (mmHg) 87 ± 11 84 ± 11b
PP (mmHg) 62 ± 18 58 ± 17b
GFR (mL/min/1.73m2) 93 ± 39 95 ± 25
Total cholesterol (mg/dL) 212 ± 37 206 ± 33a
Urea (mmol/L) 41 ± 11 42 ± 14
Sodium (mmol/L) 141 ± 4 141 ± 4
Potassium (mmol/L) 4.2 ± 0.4 4.3 ± 0.4
EF (%) 59 ± 5 59 ± 5
E/A ratio (m/s) 0.91 ± 0.25 0.94 ± 0.26
LVMI (g/m2.7) 53 ± 17 53 ± 17
Results are shown as mean ± SD or percentage of subjects. BMI: body mass
index; SBP: systolic blood pressure; DBP: diastolic blood pressure; PP: pulse
pressure; GFR: glomerular filtration rate; EF: ejection fraction; E: maximal
early mitral valve inflow; A: maximal late mitral valve inflow; LVMI: left
ventricular mass index. aP < 0.05; bP < 0.01.
correlation for MMP-2 (r = 0.55, P < 0.0001) and sTNF-R1
(r = 0.75, P < 0.0001).
When we correlated MMP-2 with well-established
parameters, we found a significant correlation with E/A ratio
(P < 0.0001), with LVMI (P < 0.0001), and with BMI
(P = 0.005). We also found a correlation between sTNF-R1
and the same parameters, with E/A (P < 0.0001), with LVMI
(P < 0.0001), and with BMI (P = 0.016). The correlation
between MMP-2 and sTNF-R1 was P < 0.0001. When we
related both molecules with cholesterol neither MMP-2 nor
sTNF-R1 were significantly correlated.
Finally, a multivariate linear regression analysis was used
to test the independent predictive power of the related
significant variables and treatment on serum log-trans-
formedMMP-2 and sTNF-R1. Neither cholesterol nor blood
pressure was independent factors of MMP-2 and sTNF-R1.
4. Discussion
The present study shows in a homogeneous and representa-
tive group of patients with clinically and functionally stable
hypertension a good stability of MMP-2 and sTNF-R1 levels.
This is the first study to monitor changes in serum MMP-
2 and sTNF-R1 concentration in a 12-month followup in
patients with essential HT.
Hypertensive heart disease is a progressive condition in
which the compensatory LVH leads to myocardial remod-
eling, characterized by fibrosis and decrease in the number
of cardiomyocytes. It has been suggested that alterations
of the collagen turnover and apoptosis may be one of the
mechanisms involved in the genesis of diastolic dysfunction
of hypertensive origin [32]. Cardiomyocyte apoptosis has
4 ISRN Cardiology
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Figure 1: Bland-Altman plots for changes in MMP-2 and sTNF-R1 serum levels in hypertensive patients. Bland-Altman plot showing
agreement between the logarithm of MMP-2 levels percentage change against the average of the logarithm of MMP-2 in basal stage + stage I,
in the hypertensive patients (a). Bland-Altman plot showing agreement between the logarithm of sTNF-R1 levels percentage change against
the average of the logarithm of sTNF-R1 in basal stage + stage I, in the hypertensive patients (b). The solid line represents the mean of the
percentage change. The dashed lines define the limits of agreement (standard deviation of percentage of change × 1.96 SD). SD: standard
deviation; MMP-2: metalloproteinase-2; sTNF-R1: soluble tumor necrosis factor receptor 1; stage I: 12-month followup.
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Figure 2: Correlation between log transformed values of MMP-2 (a) and sTNF-R1 (b) in basal stage versus stage I. MMP-2,
metalloproteinase-2; sTNF-R1: soluble tumor necrosis factor receptor 1; stage I: 12-month followup.
been shown to be abnormally stimulated in the hypertro-
phied heart of patients with essential HT [33] and moderate
cardiomyocytes loss in long-term systemic HT with no
clinical evidence of HF [34].
Because of the detrimental eﬀects that cardiomyocyte
apoptosis and fibrosis may exert in hypertensive heart
disease, to recognize and prevent or limit the magnitude
of this phenomenon may be relevant in both assessing and
modifying the clinical outcome of patients with arterial
HT. It would be of interest to monitor such processes of
apoptosis, with sTNF-R1, and abnormal ECM metabolism,
with MMP-2, in hypertensive patients by using these
molecules variability as a tool tomonitor the evolution in HT
patients and to achieve an earlier prognosis or prevention of
hypertension-induced HF. MMP-2 and sTNF-R1 are potent
predictors of cardiovascular events and mortality in HF
patients, and these biochemical markers used in conjunction
with other established markers as NT-proBNP, that is, a
powerful predictor of mortality in HT [22], may also help to
identify patients with no clinical evidence of HT, and provide
information about the need for changes in treatment during
diﬀerent stages of the disease, and potentially it could provide
valuable biochemical data for the specialist.
The main clinical consequence of this study is the
establishment of a MMP-2 and sTNF-R1 percentage change,
from which we can monitor the progress of these patients.
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Thus, we suggest that MMP-2 measured variations, with a
coeﬃcient of reproducibility (>1.96 SD percentage change)
above 8.2% and for sTNF-R1, values over 11.3% may
be considered of potential clinical value when monitoring
hypertensive patients. Although there are diﬀerences in the
average of MMP-2 levels compared with stage I versus basal
stage, with the Bland-Altman analysis we can observe that
this molecule is one of the most stable and has the lowest
coeﬃcient of reproducibility, indicating that these variations
in the average do not aﬀect its stability as a marker of
in hypertensive disease development. Furthermore, good
correlation was obtained between MMP-2 and sTNF-R1
concentrations at the two stages over the entire study, the
correlation coeﬃcients being higher for the sTNF-R1 levels
of hypertensive patients.
In our 234 patients with clinically and functionally stable
HT there were neither cardiovascular events nor diﬀerences
in ventricular function. Moreover, we found significant
diﬀerences for values of blood pressure and total cholesterol
of these variables decreasing over time probably as a conse-
quence of the treatment. At first we might think that these
changes in blood pressure values may aﬀect the molecules
concentrations during followup and thus alter its intrinsic
variability and limit the purpose of the study. However,
through the simple correlations and the multivariate linear
regression analysis carried out we can confirm that neither
blood pressure nor total cholesterol levels were independent
predictors of these molecule levels in hypertensive patients,
as other authors have pointed out [10, 35, 36]. Therefore
MMP-2 and sTNF-R1 variability could not be attributed to
their changes over time.
One limitation of this study is that our patients were
on medication and it is known that these molecule values
could be aﬀected by treatment with diuretics, angiotensin-
converting enzyme inhibitors, angiotensin II receptor block-
ers, or beta-blockers [37–40]. Nevertheless, this circumstance
makes it easier to extrapolate our data to the clinical practice.
On the other hand, we have to admit that a larger group
of patients would have provided additional information.
However, the strict inclusion-exclusion criteria give our
results greater value.
An important consideration is that we selected patients
with clinically stable HT without clinical or functional
changes, but we cannot rule out the possibility of subtle
changes in neurohormonal and immunology systems that
might potentially influence the variability of the molecule
levels. In some studies, the increase of apoptotic markers
was associated with comparable changes of other cytokine
levels, indicating that the activation of this system is also
associated with autoimmune-inflammatory reactions [41,
42]. However, we think that because of this, our data are
more useful for judging the clinical variations in these
molecule levels, and they have evident practical application.
Another potential limitation is that although echo-
cardiography-standardized techniques have been shown to
be a more sensitive tool for detecting LVH than for elec-
trocardiographic measurements, the variability of this tech-
nique is higher than the variability using magnetic reso-
nance imaging. However, in this study a specialized, blinded,
single cardiologist performed the echocardiographic analysis
to minimize variability of the measurements. Moreover, it
would have been interesting to get the filling pressures, but
the methodology used in our asymptomatic patients did not
include this measure.
5. Conclusions
This study shows that there is good stability in MMP-
2 and sTNF-R1 levels in a 12-month follow-up study of
asymptomatic patients with clinically and functionally stable
hypertension. Measured variations in MMP-2 exceeding
8.2% in a 12-month followup and for sTNF-R1, values
over 11.3% may indicate an increase in cardiovascular risk.
The low variability of these molecules suggest that their
levels could be used to monitor hypertensive patients and
optimizing medical treatment rather than blood pressure
control alone.
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